The results of the first stage of COVID-19 vaccine Sputnik V trial for adolescents aged 12 to 17 were presented in Moscow, mos.ru reports.
The first stage of the study involved 99 minors (56 boys and 43 girls) aged 12 to 17 years. Both components of the studied vaccine were received by 92 volunteers. The drug was administered in the volume of 1/10 or 1/5 of the immunizing dose aimed at adults.
The results of the first stage of the study bring us to the following conclusions:
– double vaccination of volunteers with the Gam-Covid-Vac M vaccine, both with 1/10 and with 1/5 of the adult immunizing dose, can lead to the formation of good post-vaccination cellular immunity;
– the drug showed a favorable safety and immunogenicity profile;
– safety and immunogenicity indicators exceed those in adult participants in phases 1 and 2 of a similar study.
At the moment, a preliminary selection of volunteers to participate in the second stage of the study is underway.
Earlier it became known that Generium had developed a nasal form of the Sputnik V coronavirus vaccine and applied for its trials.
